See more : Hwasung Industrial Co., Ltd. (002460.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Pharvaris N.V. (PHVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharvaris N.V., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Diales Plc (DIAL.L) Income Statement Analysis – Financial Results
- Swedish Orphan Biovitrum AB (publ) (SOBI.ST) Income Statement Analysis – Financial Results
- Sime Darby Berhad (SMEBF) Income Statement Analysis – Financial Results
- AEA-Bridges Impact Corp. (IMPX) Income Statement Analysis – Financial Results
- Emaar Properties PJSC (EMAAR.AE) Income Statement Analysis – Financial Results
Pharvaris N.V. (PHVS)
About Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 252.27K | 150.19K | 80.46K | 0.00 | 547.41 | 0.00 |
| Gross Profit | -252.27K | -150.19K | -80.46K | 0.00 | -547.41 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 65.58M | 57.38M | 35.79M | 19.51M | 5.68M | 3.65M |
| General & Administrative | 31.14M | 29.34M | 18.35M | 5.50M | 2.33M | 668.12K |
| Selling & Marketing | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.34M | 29.34M | 18.35M | 5.50M | 2.33M | 668.12K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 96.91M | 86.71M | 54.14M | 25.01M | 8.01M | 4.31M |
| Cost & Expenses | 96.91M | 86.71M | 54.14M | 25.01M | 8.01M | 4.31M |
| Interest Income | 0.00 | 16.11 | 267.51 | 92.47 | 4.38 | 0.00 |
| Interest Expense | 20.06K | 16.11K | 278.18K | 92.47K | 0.00 | 0.00 |
| Depreciation & Amortization | 59.78K | 150.19K | 80.46K | 7.40K | 547.41 | 4.31M |
| EBITDA | -96.85M | -86.58M | -54.06M | -25.01M | -8.01M | -4.31M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -96.91M | -86.74M | -65.90M | -25.01M | -7.99M | -4.31M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.91M | 11.08M | 11.48M | -1.06M | -16.88K | -380.00 |
| Income Before Tax | -99.83M | -75.65M | -42.66M | -26.07M | -8.03M | -4.31M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.05M | 679.09K | 70.12K | -83.25K | 16.88K | 380.00 |
| Net Income | -100.88M | -76.33M | -42.73M | -25.99M | -8.04M | -4.31M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.63 | -2.27 | -1.41 | -0.85 | -1.66 | -0.14 |
| EPS Diluted | -2.63 | -2.27 | -1.41 | -0.85 | -1.66 | -0.14 |
| Weighted Avg Shares Out | 38.39M | 33.59M | 30.41M | 30.52M | 4.85M | 31.84M |
| Weighted Avg Shares Out (Dil) | 38.39M | 33.59M | 30.41M | 30.52M | 4.85M | 31.84M |
Pharvaris shares surge as treatment for severe swelling meets clinical trial goal
Shares of Pharvaris N.V. PHVS, +14.98% jumped 40% premarket on Wednesday after the Switzerland-based company said an investigational drug met its primary goal in a clinical trial for treatment and prevention of hereditary angioedema attacks.
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”, Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, announced today the pricing of an underwritten offering of...
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical...
Pharvaris to Present at the GA²LEN UCARE Conference 2023
ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of one abstract for oral presentation and...
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical...
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
ZUG, Switzerland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of two ePosters at the American College of Allergy,...
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
ZUG, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the third quarter ended September 30, 2023 and...
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at...
Pharvaris To Present at the APAAACI 2023 International Conference
ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of an abstract oral presentation at the...
Pharvaris To Present at the CIIC Fall 2023 Conference
ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the Consortium...
Source: https://incomestatements.info
Category: Stock Reports